- Home
- IONS vs ELS Comparison
IONS vs ELS Comparison
Compare IONS & ELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IONS | ELS |
|---|---|---|
| Founded | 1989 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 13.2B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | IONS | ELS |
|---|---|---|
| Price | $74.88 | $63.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $92.73 | $69.83 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 04-29-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 3.34% |
| EPS Growth | ★ 21.71 | 2.55 |
| EPS | N/A | ★ 2.01 |
| Revenue | N/A | ★ $1,531,382,000.00 |
| Revenue This Year | N/A | $3.97 |
| Revenue Next Year | $77.99 | $4.69 |
| P/E Ratio | ★ N/A | $32.34 |
| Revenue Growth | N/A | ★ 0.34 |
| 52 Week Low | $28.79 | $57.63 |
| 52 Week High | $86.74 | $69.00 |
Technical Indicators
Market Signals| Indicator | IONS | ELS |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 39.15 |
| Support Level | $69.85 | $61.53 |
| Resistance Level | $77.08 | $64.06 |
| Average True Range (ATR) | 1.99 | 1.09 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 45.01 | 13.62 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt; 38% of the company's properties are in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.